Sandu Pharmaceuticals Ltd — Important, 11-08-2026: Company Update

Sandu Pharmaceuticals' board has approved the financial results for the quarter. Revenue from operations stood at 16.39 Cr, with a profit of 0.23 Cr and earnings per share of 0.37. The board also approved the annual report documents for the previous financial year. An Annual General Meeting (AGM) is scheduled, and a record date was set to determine eligibility for the proposed dividend. The company will seek shareholder approval at the AGM for continuing material related party transactions and for the appointment of M/s. Dave & Dave as statutory auditors for a five-year term.